<h1>India Continues 100% FDI in Greenfield Pharma; Brownfield Needs FIPB Approval for Six Months, CCI to Set Rules.</h1> India will maintain its policy of allowing 100% Foreign Direct Investment (FDI) in Greenfield pharmaceutical projects through the automatic route, aiming to enhance manufacturing capabilities and technology acquisition. For brownfield investments, FDI will be permitted via the Foreign Investment Promotion Board (FIPB) approval route for six months, during which the Competition Commission of India (CCI) will develop necessary regulations for oversight on mergers and acquisitions. This approach seeks to balance public health concerns with the need to attract FDI and strengthen domestic manufacturing in the pharmaceutical sector.